Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Financing Activities (2016 - 2025)

Capricor Therapeutics has reported Cash from Financing Activities over the past 15 years, most recently at $248.8 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $248.8 million for Q4 2025, up 206.85% from a year ago — trailing twelve months through Dec 2025 was $248.9 million (up 62.92% YoY), and the annual figure for FY2025 was $248.9 million, up 62.92%.
  • Cash from Financing Activities for Q4 2025 was $248.8 million at Capricor Therapeutics, up from $6950.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for CAPR hit a ceiling of $248.8 million in Q4 2025 and a floor of $3895.0 in Q1 2023.
  • Median Cash from Financing Activities over the past 5 years was $2.0 million (2022), compared with a mean of $22.6 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 58699.59% in 2024 and later crashed 99.99% in 2025.
  • Capricor Therapeutics' Cash from Financing Activities stood at $42370.0 in 2021, then surged by 6861.35% to $2.9 million in 2022, then surged by 685.45% to $23.2 million in 2023, then skyrocketed by 250.01% to $81.1 million in 2024, then skyrocketed by 206.85% to $248.8 million in 2025.
  • The last three reported values for Cash from Financing Activities were $248.8 million (Q4 2025), $6950.0 (Q3 2025), and $19580.0 (Q2 2025) per Business Quant data.